サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1475205

リウマチ治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

Global Rheumatology Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日: | 発行: Value Market Research | ページ情報: 英文 182 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.13円
リウマチ治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測
出版日: 2024年04月01日
発行: Value Market Research
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

リウマチ治療市場の世界需要は、2023年の492億1,000万米ドルから2032年には651億1,000万米ドル近くの市場規模に達すると推定され、調査期間2024～2032年のCAGRは3.16%です。

リウマチ治療とは、関節、筋肉、骨、結合組織に影響を及ぼす自己免疫疾患、炎症性疾患、変性疾患を含むリウマチ性疾患を管理・治療するための薬剤や治療法を指します。これらの治療は、痛み、炎症、こわばり、関節損傷を緩和し、疾患の進行を遅らせ、身体機能を改善し、リウマチ性疾患患者の生活水準を向上させることを目的としています。

市場力学

関節リウマチ（RA）、全身性エリテマトーデス（SLE）、変形性関節症（OA）、その他の自己免疫疾患や炎症性疾患の罹患率が上昇していることから、症状を緩和し、疾患の進行を遅らせ、生活の質を高める効果的な治療法を患者が求めるようになり、リウマチ治療の需要が高まっています。人口の高齢化、遺伝的素因、環境要因がリウマチ性疾患の世界の負担に寄与していることから、根本的な疾患メカニズムを標的とし、免疫反応を調節し、罹患者の組織の恒常性を回復させる革新的な治療に対するニーズが高まっています。

さらに、バイオ医薬品研究、免疫学、分子生物学の進歩により、従来の疾患修飾性抗リウマチ薬（DMARDs）や非ステロイド性抗炎症薬（NSAIDs）と比較して、有効性、安全性、忍容性が改善された新規生物製剤、低分子阻害剤、標的治療の開発が可能となっています。さらに、精密医療、バイオマーカー探索、薬理ゲノミクスが重視されるようになったことで、製薬企業、バイオテクノロジー新興企業、学術研究者が協力して患者のサブグループを特定し、疾患表現型を層別化し、治療成果を最適化し副作用を最小限に抑える個別化治療アルゴリズムを開発するようになり、リウマチ治療市場の革新が進んでいます。

さらに、リウマチ領域におけるバイオシミラー、バイオスーペリア、次世代治療の採用拡大により、市場競争、価格力学、革新的治療へのアクセスが促進され、医薬品開発者、医療プロバイダー、患者にとって機会と課題が生じています。しかし、バイオシミラー代替品との競合の激化や規制上のハードルは、今後数年間のリウマチ治療市場の成長に影響を与える可能性があります。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を対象としています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、リウマチ治療の世界市場における各セグメントを包括的に評価することもできます。リウマチ治療業界の成長と動向は、この調査に全体的なアプローチを記載しています。

市場セグメンテーション

リウマチ治療市場レポートのこのセクションでは、国レベルと地域レベルのセグメントに関する詳細なデータを提供することで、戦略担当者が今後のビジネス機会とともに、それぞれの製品やサービスの対象層を特定するのに役立ちます。

薬剤クラス別

  • 疾患修飾性抗リウマチ薬（Dmards）（合成疾患修飾性抗リウマチ薬、生物学的疾患修飾性抗リウマチ薬）
  • 非ステロイド性抗炎症薬（Nsaids）
  • コルチコステロイド
  • 尿酸薬
  • その他

適応疾患別

  • 関節リウマチ
  • 変形性関節症
  • 痛風
  • 乾癬性関節炎
  • 強直性脊椎炎
  • その他

投与経路別

  • 非経口
  • 経口
  • 局所

流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

地域別分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおけるリウマチ治療市場の現在と将来の需要を強調する地域展望をカバーしています。さらに、すべての主要地域における個々の用途セグメントの需要・推定・予測にも焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 リウマチ治療-産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカー一覧
    • 主要原材料の価格動向
  • 潜在的バイヤー一覧
  • マーケティングチャネル
    • 直接マーケティング
    • 間接マーケティング
    • マーケティングチャネル発展動向

第5章 世界のリウマチ治療市場分析：薬剤クラス別

  • 薬剤クラス別概要
  • 実績データと予測データ
  • 薬剤クラス別分析
  • 疾患修飾性抗リウマチ薬（DMARDs）（合成疾患修飾性抗リウマチ薬、生物学的疾患修飾性抗リウマチ薬）
  • 非ステロイド性抗炎症薬（NSAIDs）
  • 副腎皮質ステロイド薬
  • 尿酸薬
  • その他

第6章 リウマチ治療の世界市場分析：適応疾患別

  • 適応疾患別概要
  • 実績データと予測データ
  • 適応疾患別分析
  • 関節リウマチ
  • 変形性関節症
  • 痛風
  • 乾癬性関節炎
  • 強直性脊椎炎
  • その他

第7章 リウマチ治療の世界市場分析：投与経路別

  • 概要投与経路別
  • 実績データと予測データ
  • 投与経路別分析
  • 非経口
  • 経口
  • 局所

第8章 リウマチ治療の世界市場分析：流通チャネル別

  • 流通チャネル別概要
  • 実績データと予測データ
  • 流通チャネル別分析
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 リウマチ治療の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第10章 リウマチ治療企業の競合情勢

  • リウマチ治療市場の競合
  • 提携・協力・契約
  • 合併・買収
  • 新製品の上市
  • その他の開発

第11章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Genentech Inc.
  • Novartis AG
  • Johnson & Johnson Innovative Medicine
  • F. Hoffmann-La Roche AG
  • Sanofi
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Class (USD MN)
  • Disease Modifying Anti-rheumatic Drugs (DMARDs) (Synthetic Disease Modifying Anti-rheumatic Drugs, Biologic Disease Modifying Anti-rheumatic Drugs) Market Sales By Geography (USD MN)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Market Sales By Geography (USD MN)
  • Corticosteroids Market Sales By Geography (USD MN)
  • Uric Acid Drugs Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Disease Indication (USD MN)
  • Rheumatoid Arthritis Market Sales By Geography (USD MN)
  • Osteoarthritis Market Sales By Geography (USD MN)
  • Gout Market Sales By Geography (USD MN)
  • Psoriatic Arthritis Market Sales By Geography (USD MN)
  • Ankylosing Spondylitis Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Parenteral Route Market Sales By Geography (USD MN)
  • Oral Route Market Sales By Geography (USD MN)
  • Topical Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Retail Pharmacy Market Sales By Geography (USD MN)
  • Online Pharmacy Market Sales By Geography (USD MN)
  • Global Rheumatology Therapeutics Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Rheumatology Therapeutics Report
  • Market Research Process
  • Market Research Methodology
  • Global Rheumatology Therapeutics Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Class
  • Market Attractiveness Analysis By Disease Indication
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Class (USD MN)
  • Disease Modifying Anti-rheumatic Drugs (DMARDs) (Synthetic Disease Modifying Anti-rheumatic Drugs, Biologic Disease Modifying Anti-rheumatic Drugs) Market Sales By Geography (USD MN)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Market Sales By Geography (USD MN)
  • Corticosteroids Market Sales By Geography (USD MN)
  • Uric Acid Drugs Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Disease Indication (USD MN)
  • Rheumatoid Arthritis Market Sales By Geography (USD MN)
  • Osteoarthritis Market Sales By Geography (USD MN)
  • Gout Market Sales By Geography (USD MN)
  • Psoriatic Arthritis Market Sales By Geography (USD MN)
  • Ankylosing Spondylitis Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Parenteral Route Market Sales By Geography (USD MN)
  • Oral Route Market Sales By Geography (USD MN)
  • Topical Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Retail Pharmacy Market Sales By Geography (USD MN)
  • Online Pharmacy Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112114346

The global demand for Rheumatology Therapeutics Market is presumed to reach the market size of nearly USD 65.11 Billion by 2032 from USD 49.21 Billion in 2023 with a CAGR of 3.16% under the study period 2024 - 2032.

Rheumatology therapeutics refers to medications and treatments for managing and treating rheumatic diseases, encompassing autoimmune, inflammatory, and degenerative conditions affecting the joints, muscles, bones, and connective tissues. These therapeutics aim to alleviate pain, inflammation, stiffness, and joint damage, slow disease progression, improve physical function, and improve the standard of living for patients with rheumatic disorders.

MARKET DYNAMICS

The rising incidence of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), osteoarthritis (OA), and other autoimmune and inflammatory conditions drives the demand for rheumatology therapeutics as patients seek effective treatments that alleviate symptoms, slow disease progression, and enhance the quality of life. With aging populations, genetic predisposition, and environmental factors contributing to the global burden of rheumatic diseases, there is a growing need for innovative therapeutics that target underlying disease mechanisms, modulate immune responses, and restore tissue homeostasis in affected individuals.

Additionally, advancements in biopharmaceutical research, immunology, and molecular biology enable the development of novel biologics, small molecule inhibitors, and targeted therapies that offer improved efficacy, safety, and tolerability profiles compared to conventional disease-modifying anti-rheumatic drugs (DMARDs) and nonsteroidal anti-inflammatory drugs (NSAIDs). Moreover, the increasing emphasis on precision medicine, biomarker discovery, and pharmacogenomics drives rheumatology therapeutics market innovation as pharmaceutical companies, biotech startups, and academic researchers collaborate to identify patient subgroups, stratify disease phenotypes, and develop personalized treatment algorithms that optimize therapeutic outcomes and minimize adverse effects.

Furthermore, the growing adoption of biosimilars, biosuperiors, and next-generation therapeutics in rheumatology drives market competition, pricing dynamics, and access to innovative treatments, creating opportunities and challenges for drug developers, healthcare providers, and patients. However, increasing competition from biosimilar alternatives and regulatory hurdles may challenge the rheumatology therapeutics market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of rheumatology therapeutics. The growth and trends of rheumatology therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the rheumatology therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

  • Disease Modifying Anti-Rheumatic Drugs (Dmards) (Synthetic Disease Modifying Anti-Rheumatic Drugs, Biologic Disease Modifying Anti-Rheumatic Drugs)
  • Nonsteroidal Anti-Inflammatory Drugs (Nsaids)
  • Corticosteroids
  • Uric Acid Drugs
  • Others

By Disease Indication

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Gout
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Others

By Route Of Administration

  • Parenteral Route
  • Oral Route
  • Topical

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Rheumatology Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Rheumatology Therapeutics market include Merck & Co., Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Amgen, Inc., Genentech, Inc., Novartis AG, Johnson & Johnson Innovative Medicine, F. Hoffmann-La Roche AG, Sanofi. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. RHEUMATOLOGY THERAPEUTICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Disease Indication
    • 3.7.3 Market Attractiveness Analysis By Route of Administration
    • 3.7.4 Market Attractiveness Analysis By Distribution Channel
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS

  • 5.1. Overview By Drug Class
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Drug Class
  • 5.4. Disease Modifying Anti-rheumatic Drugs (DMARDs) (Synthetic Disease Modifying Anti-rheumatic Drugs, Biologic Disease Modifying Anti-rheumatic Drugs) Historic and Forecast Sales By Regions
  • 5.5. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Historic and Forecast Sales By Regions
  • 5.6. Corticosteroids Historic and Forecast Sales By Regions
  • 5.7. Uric Acid Drugs Historic and Forecast Sales By Regions
  • 5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY DISEASE INDICATION

  • 6.1. Overview By Disease Indication
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Disease Indication
  • 6.4. Rheumatoid Arthritis Historic and Forecast Sales By Regions
  • 6.5. Osteoarthritis Historic and Forecast Sales By Regions
  • 6.6. Gout Historic and Forecast Sales By Regions
  • 6.7. Psoriatic Arthritis Historic and Forecast Sales By Regions
  • 6.8. Ankylosing Spondylitis Historic and Forecast Sales By Regions
  • 6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 7.1. Overview By Route of Administration
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Route of Administration
  • 7.4. Parenteral Route Historic and Forecast Sales By Regions
  • 7.5. Oral Route Historic and Forecast Sales By Regions
  • 7.6. Topical Historic and Forecast Sales By Regions

8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 8.1. Overview By Distribution Channel
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By Distribution Channel
  • 8.4. Hospital Pharmacy Historic and Forecast Sales By Regions
  • 8.5. Retail Pharmacy Historic and Forecast Sales By Regions
  • 8.6. Online Pharmacy Historic and Forecast Sales By Regions

9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE RHEUMATOLOGY THERAPEUTICS COMPANIES

  • 10.1. Rheumatology Therapeutics Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF RHEUMATOLOGY THERAPEUTICS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Merck & Co. Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. AbbVie Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Bristol-Myers Squibb Company
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Pfizer Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Takeda Pharmaceutical Company Limited
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Amgen Inc.
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Genentech Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Novartis AG
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Johnson & Johnson Innovative Medicine
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. F. Hoffmann-La Roche AG
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Sanofi
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies